Deep sequencing of the T cell receptor visualizes reconstitution of T cell immunity in mogamulizumab-treated adult T cell leukemia

References

• Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014;15:e517−26. doi:10.1016/S1470-2045(14)70202-5. PMID:25281470.
   PubMed Web of Science ®Google Scholar
• Shimoyama M, Minato K, Tobinai K, Nagai M, Setoya T, Takenaka T, Ishihara K, Watanabe S, Hoshino H, Miwa M, et al. Atypical adult T-cell leukemia-lymphoma: diverse clinical manifestations of adult T-cell leukemia-lymphoma. Jpn J Clin Oncol 1983;13 Suppl 2:165–87. PMID:6603526.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Nakano K, Watanabe E, Ishigaki T, Ohno N, Yuji K, Oyaizu N, Asanuma S, Yamagishi M, Yamochi T, et al. CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult t-cell leukemia/lymphoma. Clin Cancer Res. 2014;20:2851–61. doi:10.1158/1078-0432.CCR-13-3169. PMID:24727323.
   PubMed Web of Science ®Google Scholar
• Ureshino H, Shindo T, Nishikawa H, Watanabe N, Watanabe E, Satoh N, Kitaura K, Kitamura H, Doi K, Nagase K, et al. Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia. Cancer Immunol Res. 2016;4:644–9. doi:10.1158/2326-6066.CIR-15-0303. PMID:27215229.
   PubMed Web of Science ®Google Scholar
• Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458–64. doi:10.1200/JCO.2007.11.9958. PMID:17968021.
   PubMed Web of Science ®Google Scholar
• Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, Tanosaki R, Kawano F, Miyazaki Y, Masuda M, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116:1369–76. doi:10.1182/blood-2009-10-247510. PMID:20479287.
   PubMed Web of Science ®Google Scholar
• Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clini Oncol. 2012;30:837–42. doi:10.1200/JCO.2011.37.3472. PMID:22312108.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada S, Tamura K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28:1591–8. doi:10.1200/JCO.2009.25.3575. PMID:20177026.
   PubMed Web of Science ®Google Scholar
• Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, Ezoe S, Kanakura Y, Sato E, Fukumori Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc. Natl. Acad. Sci. USA. 2013;110:17945–50. doi:10.1073/pnas.1316796110. PMID:24127572.
   PubMed Web of Science ®Google Scholar
• Sugata K, Yasunaga J, Miura M, Akari H, Utsunomiya A, Nosaka K, Ezoe S, Kanakura Y, Sato E, Fukumori Y, et al. Enhancement of anti-STLV-1/HTLV-1 immune responses through multimodal effects of anti-CCR4 antibody. Sci Rep. 2016;6:27150. doi:10.1038/srep27150. PMID:27250643.
   PubMed Web of Science ®Google Scholar
• Ishida T, Ito A, Sato F, Kusumoto S, Iida S, Inagaki H, Morita A, Akinaga S, Ueda R. Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma. Cancer science. 2013;104:647–50. doi:10.1111/cas.12116. PMID:23360455.
   PubMed Web of Science ®Google Scholar
• Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, Otsuka E, Henzan H, Kato K, Tomoyose T, et al. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality. J Clin Oncol. 2016;34:3426–33. doi:10.1200/JCO.2016.67.8250. PMID:27507878.
   PubMed Web of Science ®Google Scholar
• Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, Uike N, Saburi Y, Nosaka K, Utsunomiya A, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169:672–82. doi:10.1111/bjh.13338. PMID:25733162.
   PubMed Web of Science ®Google Scholar
• Yonekura K, Kanzaki T, Gunshin K, Kawakami N, Takatsuka Y, Nakano N, Tokunaga M, Kubota A, Takeuchi S, Kanekura T, et al. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis. J Dermatol. 2014;41:239–44. doi:10.1111/1346-8138.12419. PMID:24628073.
   PubMed Web of Science ®Google Scholar
• Yonekura K, Tokunaga M, Kawakami N, Takeda K, Kanzaki T, Nakano N, Kubota A, Takeuchi S, Takatsuka Y, Seto M, et al. Cutaneous Adverse Reaction to Mogamulizumab May Indicate Favourable Prognosis in Adult T-cell Leukaemia-lymphoma. Acta Derm Venereol. 2016;96:1000–2. doi:10.2340/00015555-2421. PMID:27025906.
   PubMed Web of Science ®Google Scholar
• Talvensaari K, Clave E, Douay C, Rabian C, Garderet L, Busson M, Garnier F, Douek D, Gluckman E, Charron D, et al. A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation. Blood. 2002;99:1458–64. doi:10.1182/blood.V99.4.1458. PMID:11830500.
   PubMed Web of Science ®Google Scholar
• Thomson BG, Robertson KA, Gowan D, Heilman D, Broxmeyer HE, Emanuel D, Kotylo P, Brahmi Z, Smith FO. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. Blood. 2000;96:2703–11. PMID:11023501.
   PubMed Web of Science ®Google Scholar
• Verdonck K, Gonzalez E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis. 2007;7:266–81. doi:10.1016/S1473-3099(07)70081-6. PMID:17376384.
   PubMed Web of Science ®Google Scholar
• Yasunaga J, Sakai T, Nosaka K, Etoh K, Tamiya S, Koga S, Mita S, Uchino M, Mitsuya H, Matsuoka M. Impaired production of naive T lymphocytes in human T-cell leukemia virus type I-infected individuals: its implications in the immunodeficient state. Blood. 2001;97:3177–83. doi:10.1182/blood.V97.10.3177. PMID:11342446.
   PubMed Web of Science ®Google Scholar